CASTLEMAN PETER M 4
4 · Caris Life Sciences, Inc. · Filed Jun 23, 2025
Insider Transaction Report
Form 4
CASTLEMAN PETER M
Director
Transactions
- Award
Common Stock
2025-02-27+16,129→ 16,129 total - Conversion
Common Stock
2025-06-20+10,245,906→ 10,270,906 total(indirect: By LLC) - Award
Stock Option
2025-02-27+2,500→ 2,500 totalExercise: $18.60Exp: 2035-02-27→ Common Stock (2,500 underlying) - Conversion
Series A Preferred Stock
2025-06-20−40,983,607→ 0 total(indirect: By LLC)Exercise: $0.00→ Common Stock (10,245,906 underlying)
Holdings
- 100,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.
- [F2]Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.
- [F3]CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- [F4]The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.